Christopher J Ricketts

List of Publications by Year
in descending order

63 papers	5,588 citations	126708 33 h-index	114278 63 g-index
65 all docs	65 docs citations	65 times ranked	8924 citing authors

#	Article	IF	Citations
1	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell, 2014, 26, 319-330.	7.7	665
2	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	2.9	523
3	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 2019, 179, 964-983.e31.	13.5	430
4	The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nature Reviews Urology, 2019, 16, 539-552.	1.9	357
5	Germline SDHB Mutations and Familial Renal Cell Carcinoma. Journal of the National Cancer Institute, 2008, 100, 1260-1262.	3.0	330
6	Tumor risks and genotypeÃ¢Â€Â“phenotypeÃ¢Â€Â“proteotype analysis in 358 patients with germline mutations inSDHBandSDHD. Human Mutation, 2010, 31, 41-51.	1.1	325
7	Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nature Reviews Urology, 2014, 11, 465-475.	1.9	227
8	Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nature Genetics, 2012, 44, 277-284.	9.4	219
9	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. Journal of Urology, 2012, 188, 2063-2071.	0.2	211
10	Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas. JAMA - Journal of the American Medical Association, 2010, 304, 2611.	3.8	174
11	The Metabolic Basis of Kidney Cancer. Cancer Discovery, 2019, 9, 1006-1021.	7.7	163
12	Genome-Wide DNA Methylation Profiling of CpG Islands in Breast Cancer Identifies Novel Genes Associated with Tumorigenicity. Cancer Research, 2011, 71, 2988-2999.	0.4	141
13	A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma. Molecular Cancer Research, 2013, 11, 1061-1071.	1.5	135
14	The metabolic basis of kidney cancer. Seminars in Cancer Biology, 2013, 23, 46-55.	4.3	132
15	New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease. Clinical Cancer Research, 2015, 21, 10-17.	3.2	88
16	Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. Cancer Cell, 2014, 26, 840-850.	7.7	87
17	Sodium-potassium ATPase 1 subunit is a molecular partner of Wolframin, an endoplasmic reticulum protein involved in ER stress. Human Molecular Genetics, 2007, 17, 190-200.	1.4	85
18	Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma. PLoS ONE, 2013, 8, e72179.	1.1	80

#	Article	IF	Citations
19	Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN. Clinical Cancer Research, 2008, 14, 5925-5930.	3.2	64
20	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydrataseâ€“deficient renal cancer. Science Signaling, 2021, 14, .	1.6	64
21	Mutations in FLVCR2 Are Associated with Proliferative Vasculopathy and Hydranencephaly-Hydrocephaly Syndrome (Fowler Syndrome). American Journal of Human Genetics, 2010, 86, 471-478.	2.6	60
22	Tumor-Specific Hypermethylation of Epigenetic Biomarkers, Including SFRP1, Predicts for Poorer Survival in Patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) Project. PLoS ONE, 2014, 9, e85621.	1.1	58
23	Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC). PLoS ONE, 2015, 10, e0140257.	1.1	56
24	A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genetics, 2012, 205, 377-390.	0.2	55
25	Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics, 2012, 7, 278-290.	1.3	54
26	Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. Anticancer Research, 2009, 29, 4337-43.	0.5	52
27	Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocrine-Related Cancer, 2010, 18, 73-83.	1.6	49
28	Intratumoral heterogeneity in kidney cancer. Nature Genetics, 2014, 46, 214-215.	9.4	44
29	Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma. PLoS ONE, 2009, 4, e6037.	1.1	40
30	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. Urology, 2014, 83, 1225-1232.	0.5	40
31	Transcriptional Regulation of Cyclin A2 by RASSF1A through the Enhanced Binding of p120E4F to the Cyclin A2 Promoter. Cancer Research, 2005, 65, 2690-2697.	0.4	39
32	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. Journal of Clinical Oncology, 2020, 38, 1146-1153.	0.8	39
33	Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma. Cell, 2018, 173, 540-542.	13.5	37
34	SnapShot: Renal Cell Carcinoma. Cancer Cell, 2016, 29, 610-610.e1.	7.7	35
35	Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. Oncotarget, 2018, 9, 10723-10733.	0.8	35
36	Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. Blood, 2021, 137, 126-137.	0.6	29

#	Article	IF	Citations
37	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, earlyâ€onset disease. Cancer, 2019, 125, 1060-1069.	2.0	28
38	Discoveries, therapies and opportunities. Nature Reviews Urology, 2014, 11, 614-616.	1.9	24
39	Patient-specific factors influence somatic variation patterns in von Hippelâ€“Lindau disease renal tumours. Nature Communications, 2016, 7, 11588.	5.8	24
40	Targeting HIF2Î± in Clear-Cell Renal Cell Carcinoma. Cancer Cell, 2016, 30, 515-517.	7.7	23
41	Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. Urology, 2021, 149, 89-97.	0.5	22
42	Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. Genes Chromosomes and Cancer, 2017, 56, 484-492.	1.5	21
43	CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. Urology, 2019, 124, 91-97.	0.5	20
44	<scp>UBE</scp> 2 <scp>QL</scp> 1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene. Human Mutation, 2013, 34, 1650-1661.	1.1	18
45	Subcellular distribution of lowâ€voltage activated Tâ€type Ca²⁺ channel subunits (Ca_v3.1 and Ca_v3.3) in reticular thalamic neurons of the cat. Journal of Neuroscience Research, 2010, 88, 448-460.	1.3	17
46	RCC â€" advances in targeted therapeutics and genomics. Nature Reviews Urology, 2017, 14, 76-78.	1.9	14
47	Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). Genes Chromosomes and Cancer, 2017, 56, 719-729.	1.5	14
48	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget, 2017, 8, 17628-17642.	0.8	11
49	Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc. Scientific Reports, 2019, 9, 18409.	1.6	10
50	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. Genes Chromosomes and Cancer, 2021, 60, 434-446.	1.5	10
51	Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1221-1223.	7.7	8
52	A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau. Journal of Medical Genetics, 2020, , jmedgenet-2020-107308.	1.5	8
53	Novel renal medullary carcinoma cell lines, <scp>UOK353</scp> and <scp>UOK360</scp>, provide preclinical tools to identify new therapeutic treatments. Genes Chromosomes and Cancer, 2020, 59, 472-483.	1.5	7
54	The origin, evolution and route to metastasis of clear cell RCC. Nature Reviews Nephrology, 2018, 14, 538-540.	4.1	6

#	Article	IF	Citations
55	Comprehensive characterization of Alu â€mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. Human Mutation, 2021, 42, 520-529.	1.1	6
56	Complexities in estimating the true risk of hereditary leiomyomatosis and renal cell carcinoma and the development of kidney cancer. Cancer, 2020, 126, 3617-3619.	2.0	5
57	Multifocal Renal Cell Carcinomas With Somatic IDH2 Mutation: Report of a Previously Undescribed Neoplasm. American Journal of Surgical Pathology, 2021, 45, 137-142.	2.1	5
58	Summary from the Kidney Cancer Associationâ€™s Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer, 2021, 19, 167-175.	0.9	4
59	New Insights into von Hippel-Lindau Function Highlighted by Investigation of the Trichloroethylene-Induced p.P81S Hotspot Mutation. Journal of the National Cancer Institute, 2013, 105, 1339-1340.	3.0	3
60	Papillary Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 1990-1991.	13.9	3
61	MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2021, 12, 5375-5384.	1.2	2
62	Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease. Urology, 2022, 165, 170-177.	0.5	2
63	Metabolic evaluation of sporadic papillary kidney cancer.. Journal of Clinical Oncology, 2012, 30, 377-377.	0.8	0